[go: up one dir, main page]

KR970706842A - 아실화된 인슐린 동족체(Acylated Insulin Analogs) - Google Patents

아실화된 인슐린 동족체(Acylated Insulin Analogs)

Info

Publication number
KR970706842A
KR970706842A KR1019970703179A KR19970703179A KR970706842A KR 970706842 A KR970706842 A KR 970706842A KR 1019970703179 A KR1019970703179 A KR 1019970703179A KR 19970703179 A KR19970703179 A KR 19970703179A KR 970706842 A KR970706842 A KR 970706842A
Authority
KR
South Korea
Prior art keywords
insulin
acylated
homologue
lys
seq
Prior art date
Application number
KR1019970703179A
Other languages
English (en)
Inventor
제프리 클레이튼 베이커
죠제 미샤엘 앙뀌에
Original Assignee
피터 쥐. 스트링거
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피터 쥐. 스트링거, 일라이 릴리 앤드 캄파니 filed Critical 피터 쥐. 스트링거
Publication of KR970706842A publication Critical patent/KR970706842A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

본 발명은 당뇨병 분야에 관한 것이다. 더 특히, 본 발명은 A 사슬은 천연의 사람 인슐린 A 서열이고, B 사슬은 B28 및 B29, 또는 모두에서 변경된, 단량체성 인슐린 동족체에 관한 것이다. 동족체는 A 사슬 또는 B 사슬의 N-말단 또는 라이신에서 일아실화된다. 아실화된 인슐린 동족체는 작용 지속시간이 연장된다.

Description

아실화된 인슐린 동족체(Acylated Insulin Analogs)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 서열 동정 번호 2에 적절하에 가교결합된 서열 동정 번호 1로 나타내어지는 일아실화된 인슐린 동족체, 또는 제약학적으로 허용가능한 그의 염.
  2. 제1항에 있어서, 서열 동정 번호 2의 28위치에서의 Xaa가 아실화된 라이신이고, 서열 동정 번호 2의 29위치에서의 Xaa가 프롤린인 아실화된 인슐린 동족체.
  3. 제2항에 있어서, 아실화기가 C6-C17지방산인 아실화된 인슐린 동족체.
  4. 제2항에 있어서, 아실화기가 C13-C17지방산인 아실화된 인슐린 동족체.
  5. B28-Nε-팔미토일-LysB28ProB29-사람 인슐린.
  6. B28-Nε-미리스토일-LysB28ProB29-사람 인슐린.
  7. 제1항 내지 6항 중 어느 한 항의 인슐린 동족체를 하나 이상의 제약학적으로 허용가능한 보존제, 등장화제 또는 완충제가 함께 포함하는 비경구 제약 제제.
  8. 인술린 또는 인슐린 동족체와 제1항 내지 7항 중 어느 한 항의 아실화된 인슐린 동족체와의 혼합물을 포함하고, 2가지 성분의 중량비가 약 1∼99 : 99∼1인 비경구 제약 제제.
  9. 제8항에 있어서, 혼합물이 LysB28ProB29-사람 인슐린과 B28-Nε-아실화된-LysB28ProB29-사람 인슐린의 혼합물인 비경구 제약 제제.
  10. 제1항 내지 7항 중 어느 한 항의 아실화된 인슐린 동족체의 유효량을 포함하는 제약 조성물을 환자에게 투여하는 것을 포함하는, 고혈당증 환자의 치료 방법.
  11. 제1항 내지 7항 중 어느 한 항의 화합물, 등장화제 및 생리적으로 허용되는 완충제를 혼합하는 것을 포함하는 비경구 제약 제제의 제조 방법.
  12. 당뇨병 치료에서 유용한 제1항 내지 7항 중 어느 한 항에 따른 아실화된 인슐린 동족체.
  13. 실질적으로 모든 실시예에 기재된 아실화된 인슐린 동족체.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703179A 1994-11-17 1995-11-14 아실화된 인슐린 동족체(Acylated Insulin Analogs) KR970706842A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/342,931 1994-11-17
US08/342,931 US5693609A (en) 1994-11-17 1994-11-17 Acylated insulin analogs

Publications (1)

Publication Number Publication Date
KR970706842A true KR970706842A (ko) 1997-12-01

Family

ID=23343907

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703179A KR970706842A (ko) 1994-11-17 1995-11-14 아실화된 인슐린 동족체(Acylated Insulin Analogs)

Country Status (25)

Country Link
US (2) US5693609A (ko)
EP (1) EP0712861B1 (ko)
JP (1) JPH10511644A (ko)
KR (1) KR970706842A (ko)
AR (1) AR002700A1 (ko)
AT (1) ATE237635T1 (ko)
AU (1) AU711282B2 (ko)
BR (1) BR9509653A (ko)
CA (1) CA2205060A1 (ko)
CO (1) CO4520284A1 (ko)
CZ (1) CZ145797A3 (ko)
DE (1) DE69530353T2 (ko)
ES (1) ES2194890T3 (ko)
FI (1) FI972031L (ko)
HU (1) HUT77030A (ko)
IL (1) IL115973A (ko)
NO (1) NO972169L (ko)
NZ (1) NZ297257A (ko)
PL (1) PL320644A1 (ko)
RU (1) RU2160118C2 (ko)
TR (1) TR199501420A2 (ko)
TW (1) TW434259B (ko)
WO (1) WO1996015804A1 (ko)
YU (1) YU71395A (ko)
ZA (1) ZA959679B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190102063A (ko) * 2017-01-05 2019-09-02 코덱시스, 인코포레이티드 페니실린 ｇ 아실라아제

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0537524A1 (en) * 1991-10-17 1993-04-21 Shipley Company Inc. Radiation sensitive compositions and methods
GB9316895D0 (en) 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US6417326B1 (en) * 1996-04-11 2002-07-09 The University Of British Columbia Fusogenic liposomes
US5948751A (en) * 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
EP2016950B1 (en) 1996-08-08 2011-01-05 Amylin Pharmaceuticals, Inc. Pharmaceutical composition comprising an exendin-4 peptide
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
EA200000453A1 (ru) * 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US6159931A (en) * 1998-09-29 2000-12-12 The Ohio State University Lipid-modified insulin incorporated liposomes for selectively delivering cytotoxic agents to hepatoma cells
AU4904800A (en) 1999-05-27 2000-12-18 Robert Z-T. Luo Identification of compounds for modulating dimeric receptors
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
ATE461692T1 (de) * 1999-10-29 2010-04-15 Novartis Ag Trockenpulverzusammensetzungen mit verbesserter dispersität
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7905230B2 (en) * 2001-05-09 2011-03-15 Novartis Ag Metered dose inhaler with lockout
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1397173A1 (en) * 2001-06-20 2004-03-17 Nektar Therapeutics Powder aerosolization apparatus and method
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
MXPA04003597A (es) * 2001-10-18 2004-07-30 Nektar Therapeutics Al Corp Conjugados polimericos de antagonistas opiaceos.
WO2003057564A1 (en) * 2001-12-21 2003-07-17 Nektar Therapeutics Apparatus and method for sealing cavities
WO2003057593A1 (en) 2001-12-21 2003-07-17 Nektar Therapeutics Capsule package with moisture barrier
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US6941980B2 (en) * 2002-06-27 2005-09-13 Nektar Therapeutics Apparatus and method for filling a receptacle with powder
AU2003285009B2 (en) * 2002-10-23 2010-10-07 Virxsys Corporation Screening methods for identification of efficient pre-trans-splicing molecules
US7516741B2 (en) * 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
US20050236296A1 (en) * 2002-12-30 2005-10-27 Nektar Therapeutics (Formerly Inhale Therapeutic Systems, Inc.) Carry case for aerosolization apparatus
KR20050088243A (ko) 2002-12-30 2005-09-02 넥타르 테라퓨틱스 프리필름화 분무기
US7669596B2 (en) * 2002-12-31 2010-03-02 Novartis Pharma Ag Aerosolization apparatus with rotating capsule
WO2004060406A2 (en) 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
ATE549051T1 (de) * 2003-04-09 2012-03-15 Novartis Ag Aerosol-gerät mit lufteinlassschild
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
JP4542090B2 (ja) * 2003-04-09 2010-09-08 ネクター セラピューティクス カプセル穿刺整合ガイドを有するエアロゾル化装置
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
ATE433994T1 (de) * 2003-07-25 2009-07-15 Conjuchem Biotechnologies Inc Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung
PT1675622T (pt) 2003-09-17 2017-09-19 Nektar Therapeutics Pró-fármacos de polímeros de múltiplos braços
US20050214224A1 (en) * 2003-11-04 2005-09-29 Nektar Therapeutics Lipid formulations for spontaneous drug encapsulation
US20050214250A1 (en) 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
AU2004297228A1 (en) 2003-12-03 2005-06-23 Nektar Therapeutics Al, Corporation Method of preparing maleimide functionalized polymers
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
PT1694363E (pt) 2003-12-16 2014-02-20 Nektar Therapeutics Composições monodispersas de naloxol peguilado
EP1701714A2 (en) * 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US8562965B2 (en) 2004-05-03 2013-10-22 Nektar Therapeutics Polymer derivatives comprising an acetal or ketal branching point
WO2005107815A2 (en) * 2004-05-03 2005-11-17 Nektar Therapeutics Al, Corporation Polymer derivatives comprising an imide branching point
KR20070029247A (ko) 2004-07-08 2007-03-13 노보 노르디스크 에이/에스 폴리펩티드 연장 태그
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006082205A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
CN101184522B (zh) * 2005-05-18 2011-12-21 尼克塔治疗公司 用于支气管内治疗的阀、设备和方法
ES2341285T3 (es) 2005-07-19 2010-06-17 Nektar Therapeutics Metodo para preparar maleimidas polimericas.
AU2006275473B2 (en) * 2005-07-29 2012-07-05 Nektar Therapeutics Methods for preparing carbonate esters of poly(ethylene glycol)
US9056921B2 (en) 2005-08-16 2015-06-16 Novo Nordisk A/S Method for making mature insulin polypeptides
AU2006297394B9 (en) * 2005-09-29 2013-09-19 Novartis Ag Receptacles and kits, such as for dry powder packaging
US20070116649A1 (en) 2005-09-29 2007-05-24 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
WO2007074133A2 (en) 2005-12-28 2007-07-05 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
SI1984009T1 (sl) 2006-01-18 2013-02-28 Qps, Llc Farmacevtski sestavki z izboljĺ ano stabilnostjo
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2015770B1 (en) * 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
US20090306337A1 (en) * 2006-07-31 2009-12-10 Novo Nordisk A/S Pegylated, Extended Insulins
BRPI0717098B8 (pt) 2006-09-22 2021-05-25 Novo Nordisk As análogos de insulina humana resistentes à protease, composição farmacêutica e processo para sua preparação
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
EP2077882A2 (en) * 2006-10-25 2009-07-15 Nektar Therapeutics Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
HUE026884T2 (en) 2007-02-11 2016-08-29 Map Pharmaceuticals Inc DHE is a therapeutic method of administration for the rapid relief of migraine while minimizing side effects
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
EP2497462A1 (en) * 2007-06-01 2012-09-12 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
KR20100098610A (ko) * 2007-10-25 2010-09-08 노파르티스 아게 단위 투여량의 약물 포장물의 분말 컨디셔닝
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
PT2910570T (pt) 2008-03-18 2017-01-24 Novo Nordisk As Análogos de insulina acilados, estabilizados contra proteases
RS53238B (en) 2008-04-04 2014-08-29 Nektar Therapeutics AEROSOLIZATION DEVICE
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8575102B2 (en) * 2008-08-01 2013-11-05 Nektar Therapeutics Conjugates having a releasable linkage
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
EP2331139B1 (en) 2008-09-11 2019-04-17 Nektar Therapeutics Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
US8680263B2 (en) * 2008-09-19 2014-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
JP2012516339A (ja) 2009-01-28 2012-07-19 スマートセルズ・インコーポレイテツド 外因的刺激型制御放出物質体およびその使用
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
EP2391646B1 (en) 2009-01-28 2016-08-10 Smartcells, Inc. Crystalline insulin-conjugates
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
JP2012520890A (ja) 2009-03-18 2012-09-10 インカーダ セラピューティクス， インコーポレイテッド 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
WO2011009131A1 (en) 2009-07-17 2011-01-20 Nektar Therapeutics Negatively biased sealed nebulizers systems and methods
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
AU2011207583B2 (en) 2010-01-19 2015-11-19 Nektar Therapeutics Identifying dry nebulizer elements
US8933207B2 (en) 2010-07-28 2015-01-13 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2598522A4 (en) 2010-07-28 2014-11-12 Smartcells Inc RECOMBINANT LECTINES, LECTINES WITH MODIFIED BINDING SITE AND USES THEREOF
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
ES2924032T3 (es) 2011-12-16 2022-10-04 Novartis Ag Aparato de aerosolización de polvo pasivo
KR20150002777A (ko) 2012-04-11 2015-01-07 노보 노르디스크 에이/에스 인슐린 제제
MX2014012512A (es) 2012-04-16 2015-01-15 Cantab Biopharmaceuticals Patents Ltd Agentes terapeuticos para administracion subcutanea optimizados.
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
WO2017127420A1 (en) 2016-01-19 2017-07-27 Nektar Therapeutics Sealed liquid reservoir for a nebulizer
SG11201805788WA (en) 2016-02-01 2018-08-30 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
HUE060149T2 (hu) 2016-12-16 2023-02-28 Novo Nordisk As Inzulint tartalmazó gyógyászati készítmények
JP2020519628A (ja) 2017-05-10 2020-07-02 インカーダ セラピューティクス， インコーポレイテッド 肺投与によって心臓の状態を処置するための単位用量、エアロゾル、キットおよび方法
WO2019034726A1 (en) 2017-08-17 2019-02-21 Novo Nordisk A/S NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
US10744087B2 (en) 2018-03-22 2020-08-18 Incarda Therapeutics, Inc. Method to slow ventricular rate
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020251983A1 (en) 2019-06-10 2020-12-17 Respira Therapeutics, Inc. Carrier-based formulations and related methods
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
KR20230009499A (ko) * 2020-05-15 2023-01-17 일라이 릴리 앤드 캄파니 연장된 시간 작용 아실화된 인슐린 화합물
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1902865A1 (de) * 1968-02-01 1969-09-11 American Home Prod Substituierte Insulin-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung in pharmazeutischen Zubereitungen
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) * 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
BE791949A (fr) * 1971-11-27 1973-05-28 Schering Ag Derives d'insuline, leur preparation et leur utilisation
US3896437A (en) * 1973-10-11 1975-07-22 Sperry Rand Corp Apparatus for generating precise crossover frequency of two independent equal bandwidth spectra
GB1492997A (en) * 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
SK282495B6 (sk) * 1993-09-17 2002-02-05 Novo Nordisk A/S Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE69629210T2 (de) * 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190102063A (ko) * 2017-01-05 2019-09-02 코덱시스, 인코포레이티드 페니실린 ｇ 아실라아제

Also Published As

Publication number Publication date
JPH10511644A (ja) 1998-11-10
AU4237396A (en) 1996-06-17
DE69530353D1 (de) 2003-05-22
NZ297257A (en) 1999-05-28
EP0712861A3 (en) 1998-03-11
ES2194890T3 (es) 2003-12-01
IL115973A (en) 2001-08-26
US5693609A (en) 1997-12-02
AU711282B2 (en) 1999-10-07
PL320644A1 (en) 1997-10-13
DE69530353T2 (de) 2004-02-19
RU2160118C2 (ru) 2000-12-10
FI972031L (fi) 1997-05-14
YU71395A (sh) 1998-07-10
CZ145797A3 (en) 1997-12-17
TW434259B (en) 2001-05-16
EP0712861B1 (en) 2003-04-16
CA2205060A1 (en) 1996-05-30
AR002700A1 (es) 1998-04-29
BR9509653A (pt) 1997-09-16
WO1996015804A1 (en) 1996-05-30
TR199501420A2 (tr) 1996-06-21
MX9703508A (es) 1997-07-31
EP0712861A2 (en) 1996-05-22
US5922675A (en) 1999-07-13
HUT77030A (hu) 1998-03-02
NO972169D0 (no) 1997-05-12
ZA959679B (en) 1997-05-14
FI972031A0 (fi) 1997-05-13
NO972169L (no) 1997-05-12
ATE237635T1 (de) 2003-05-15
IL115973A0 (en) 1996-01-31
CO4520284A1 (es) 1997-10-15

Similar Documents

Publication Publication Date Title
KR970706842A (ko) 아실화된 인슐린 동족체(Acylated Insulin Analogs)
RU97110125A (ru) Ацилированные аналоги инсулина
DE69831673T2 (de) Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
KR950703999A (ko) 변성된 인슐린-유사 성장인자(modified insulin-like growth factors)
RU2010151656A (ru) Аналоги глюкагона, обладающие повышенной растворимостью и стабильностью в буферах с физиологическими значениями ph
JP2003519667A (ja) トリグリセリドレベルの調節および脂質異常血症の治療のためのエキセンジンおよびそのアゴニストの使用
EP1234586A3 (en) Hepatoselective pharmaceutical actives
UA26874C2 (uk) Пареhтеральhа фармацевтичhа композиція
WO1998030231A9 (en) Use of exendins and agonists thereof for the reduction of food intake
BR9813111A (pt) Composições de insulina insolúveis
KR880000463A (ko) 사슬 결합법
AU2010200224A1 (en) GRF Analog Compositions and Their Use
KR880001701A (ko) 신규한 펩티드
KR950701818A (ko) 탈-tyr 다이놀핀 동족체(des-tyr dynorphin analogues)
FI93308C (fi) Menetelmä somatostatiinia sisältävän farmaseuttisen ainekoostumuksen valmistamiseksi
NO178914B (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av Diabetes mellitus
KR900003205A (ko) 제약 화합물
SE8204874D0 (sv) Farmaceutiska preparat, innefattande humant insulin och humant proinsulin
KR927002373A (ko) 성장 호르몬 분비 활성을 갖는 폴리펩타이드 화합물
KR910000794A (ko) Vip-유사체 ⅱ
DE60028559T2 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
AR032461A1 (es) Componente farmaceutico que comprende un peptido de la hormona paratiroidea humana o su derivado y acido acetico, composicion farmaceutica para la administracion intranasal que comprende dicho componente, y producto farmaceutico que comprende dicho componente
CN1060178C (zh) 新的结构改性的活性肠肽衍生物、其药物组合物及其治疗男性阳痿的应用
SE9201584D0 (sv) Use of alpha-ketoglutarate
RU95120588A (ru) Циклогексапептиды, их смеси, способ их получения и применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20001113

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20030227

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030515

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20030227

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I